Contrasting Pieris Pharmaceuticals (NASDAQ:PIRS) & PPD (NASDAQ:PPD)

Pieris Pharmaceuticals (NASDAQ:PIRS) and PPD (NASDAQ:PPD) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, dividends and analyst recommendations.

Insider and Institutional Ownership

68.3% of Pieris Pharmaceuticals shares are owned by institutional investors. Comparatively, 2.4% of PPD shares are owned by institutional investors. 6.6% of Pieris Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Pieris Pharmaceuticals and PPD’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Pieris Pharmaceuticals $46.28 million 3.47 -$25.47 million ($0.56) -5.48
PPD $4.03 billion 2.39 $341.61 million $0.98 28.22

PPD has higher revenue and earnings than Pieris Pharmaceuticals. Pieris Pharmaceuticals is trading at a lower price-to-earnings ratio than PPD, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations for Pieris Pharmaceuticals and PPD, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pieris Pharmaceuticals 0 0 3 0 3.00
PPD 0 0 14 0 3.00

Pieris Pharmaceuticals presently has a consensus price target of $7.00, indicating a potential upside of 128.01%. PPD has a consensus price target of $30.85, indicating a potential upside of 11.52%. Given Pieris Pharmaceuticals’ higher possible upside, research analysts plainly believe Pieris Pharmaceuticals is more favorable than PPD.

Profitability

This table compares Pieris Pharmaceuticals and PPD’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Pieris Pharmaceuticals -42.26% -61.01% -16.82%
PPD N/A N/A N/A

Summary

PPD beats Pieris Pharmaceuticals on 8 of the 12 factors compared between the two stocks.

Pieris Pharmaceuticals Company Profile

Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids. Its lead respiratory program includes PRS-060, a drug candidate, which is in Phase I clinical trial that binds to IL-4Ra for the treatment of asthma and other inflammatory diseases; and lead immuno-oncology program comprises PRS-343, a bispecific protein that is in Phase I clinical trial for oncology diseases. The company is also developing PRS-344, a bispecific anticalin-antibody fusion protein that is in preclinical stage for oncology diseases; and PRS-080, a polyethylene glycol conjugated anticalin protein that is in Phase IIa clinical trial to target hepcidin for the treatment of functional iron deficiency in anemic patients with chronic kidney disease or in end-stage renal disease patients requiring dialysis, as well as other drugs. It has strategic partnerships with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seattle Genetics Inc., as well as others; and non-strategic license or option agreements with Aska Pharmaceutical Co., Ltd., F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc., and Sanofi, as well as license agreements with TUM, Enumeral Biomedical Holdings, Inc., and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. Pieris Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.

PPD Company Profile

PPD, Inc. provides drug development services to the biopharmaceutical industry worldwide. The company offers clinical development and laboratory services to the pharmaceutical, biotechnology, and medical device and government organizations, as well as other industry participants. It operates in two segments, Clinical Development Services and Laboratory Services. The Clinical Development Services segment provides product development and consulting, early development, Phases II-IV clinical trial management, accelerated enrollment, peri- and post-approval, and medical communications services. The Laboratory Services segment offers bioanalytical, biomarker, vaccine science, good manufacturing practice, and central laboratory services. The company operates in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. PPD, Inc. was founded in 1985 and is headquartered in Wilmington, North Carolina.

Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply